Jacobio Pharmaceuticals Group Co., Ltd. (HK:1167) has released an update.
Jacobio Pharmaceuticals has announced that China’s NMPA has accepted and granted priority review for their new drug application for Glecirasib, aimed at treating non-small cell lung cancer with a specific mutation. The drug has shown promising results in clinical trials, with nearly half the patients experiencing significant tumor reduction, and is also being tested for other cancers. However, there is a cautionary note that Glecirasib’s development and marketing success is not guaranteed.
For further insights into HK:1167 stock, check out TipRanks’ Stock Analysis page.
